With FDA clearing Takeda’s orexin agonist for narcolepsy type 1, sleep medicine is seeing a clearer shift toward mechanism-defined treatments rather than symptom-first approaches. The twice-daily pill adds to a growing portfolio of therapies designed to target underlying biology in sleep disorders. The decision also comes as companies and clinicians increasingly prioritize patient selection criteria and measurable clinical endpoints aligned to mechanism. That focus can shape how future trials are designed and how payers evaluate evidence for coverage. For the biotech industry, the approval reiterates that neurostimulation and neuroendocrine pathways remain active areas for drug differentiation and commercialization.